What KRAS mutations, if any, would you omit when using daraxonrasib in patients with metastatic pancreatic adenocarcinoma?
80% of patients has KRAS G12D/V and 90% any G12 (G12X), leaving KRAS G13 and Q61 underrepresented. If you'd offer testing for all mutations and RAS WT, what molecular testing prior to initiating treatment would you recommend? O'Reilly et al., PMID 42223072
Community PollStarted
Which patients with metastatic pancreas cancer, based off KRAS mutational status, will you offer daraxonrasib?
164 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Wisconsin
Answered on
There is no reason to exclude any RAS mutation or RAS wild-type tumors. All types demonstrated benefit in the RASolute 302 study, albeit in smaller numbers. All PDAC patients should be considered for daraxonrasib in the second-line setting, as it is superior to second-line chemo.
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Medical College of Wisconsin
Answered on
The phase I study may shed some light on this matter (O'Reilly et al., PMID 42223072). The non-G12 in this population, as mentioned in the footnote of Table 3, were: KRAS G13D (1 patient), KRAS Q61H (14 patients), KRAS Q61R (2 patients), and KRAS Q61K (2 patients). So fair to say that this study had...
Join for free or sign in to see the full answer